|
Mean Age of onset, year
|
33.28 (15–62)
|
|
Sex (n%)
|
|
Female
|
30 (93.75%)
|
|
Male
|
2 (6.25%)
|
|
Mean BMI
|
24.17 (17.57–31.65)
|
|
Mean Disease duration, months
|
85.56 (19–266)
|
|
Mean Duration of AZA therapy, months
|
21.50 (12–40)
|
|
Clinical symptoms at onset (n%)
|
|
Optic neuritis
|
21 (65.6%)
|
|
Bilateral Optic neuritis
|
17 (53.13%)
|
|
Myelitis
|
29 (90.6%)
|
|
Optic neuritis and Myelitis
|
19 (59.3%)
|
|
Mean Pre-therapy EDSS score
|
5.21 ± 0.24 (2.5–8)
|
|
Mean Post- therapy EDSS score
|
2.57 ± 0.33 (0–7)
|
|
Mean Concentration of CSF protein, mg/dl
|
40.41 ± 32.67 (12–184)
|
|
Mean Concentration of CSF IgG, mg/ml
|
0.04 ± 0.03 (0.01–0.19)
|
|
CSF IgG index (n%)
|
0.53 ± 0.10 (0.39–0.83)
|
|
Serum anti-AQP4 antibodies (n%)
|
14 (43.75%)
|
|
Mean Concentration of 6-TGNs, pmol/8 × 108 RBC
|
202.03
|
|
Mean Concentration of MMPNs, pmol/8 × 108 RBC
|
1618.90
|
|
Relapse, n%
|
12/32 (37.5%)
|
|
Pre- therapy ARR
|
1.42 ± 0.23 (0.2–3.5)
|
|
Post- therapy ARR
|
0.36 ± 0.09 (0–1.72)
|
